Investment Thesis
Elite Pharmaceuticals demonstrates exceptional financial health with robust profitability metrics (50.2% gross margin, 36.0% operating margin, 24.4% net margin) and strong revenue growth of 48.4% YoY. The company maintains fortress-like balance sheet strength with minimal leverage (0.02x debt/equity), exceptional liquidity (7.34x current ratio), and substantial free cash flow generation of $14.1M, providing strategic flexibility for growth initiatives.
Strengths
- Exceptional profitability with 50.2% gross margin and 36.0% operating margin indicating strong pricing power and operational efficiency
- Strong revenue growth of 48.4% YoY demonstrates robust market demand and successful commercialization
- Fortress balance sheet with minimal debt (0.02x debt/equity), $21.1M cash, and 7.34x current ratio providing financial flexibility
- Outstanding returns on equity (32.9%) and assets (20.9%) indicating efficient capital deployment
- Robust free cash flow of $14.1M with 13.0% FCF margin supporting sustainability of operations and potential reinvestment
Risks
- Concerning EPS decline of -100% despite flat net income suggests significant equity dilution and share issuance
- Flat net income growth (0.0% YoY) despite 48.4% revenue growth indicates margin compression or one-time charges requiring investigation
- Limited insider activity with only 1 Form 4 filing in last 90 days suggests minimal insider confidence signals
- Pharmaceutical sector regulatory and patent cliff risks could impact future revenue sustainability and profitability
Key Metrics to Watch
- Net income growth trajectory relative to revenue growth to assess margin sustainability
- EPS recovery and share dilution trends to understand capital structure changes
- Free cash flow consistency and conversion from operating cash flow
- Gross margin stability amid competitive pricing pressures
- Debt levels and capital allocation decisions for shareholder returns
Financial Metrics
Revenue
108.1M
Net Income
26.4M
EPS (Diluted)
$0.02
Free Cash Flow
14.1M
Total Assets
126.4M
Cash
21.1M
Profitability Ratios
Gross Margin
50.2%
Operating Margin
36.0%
Net Margin
24.4%
ROE
32.9%
ROA
20.9%
FCF Margin
13.0%
Balance Sheet & Liquidity
Current Ratio
7.34x
Quick Ratio
5.44x
Debt/Equity
0.02x
Debt/Assets
36.5%
Interest Coverage
460.63x
Long-term Debt
1.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-24T05:32:11.406667 |
Data as of: 2025-12-31 |
Powered by Claude AI